Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APP | P05067 | 3/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.35 |
| ▸ | PDE10A | Q9Y233 | 7/20 | 0.35 |
| ▸ | CNR2 | P34972 | 2/20 | 0.34 |
| ▸ | CNR1 | P21554 | 1/20 | 0.34 |
| ▸ | CSF1R | P07333 | 2/20 | 0.33 |
| ▸ | IDO1 | P14902 | 1/20 | 0.33 |
| ▸ | AGXT | P21549 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | ABHD6 | Q9BV23 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20564905 | 0.80 | AR (0.38) | APPALDH1A1LMNAHTTNPSR1 | |
| SCHEMBL20564007 | 0.77 | HTR6 (0.40) | APPHRH4PDE10ACNR2CNR1 | |
| SCHEMBL20564297 | 0.74 | APP (0.35) | APPALDH1A1LMNAHTTNPSR1 | |
| SCHEMBL20564305 | 0.70 | EEF2K (0.33) | — | |
| SCHEMBL20564181 | 0.70 | CSF1R (0.43) | ALDH1A1LMNAHTTNPSR1HRH4 | |
| SCHEMBL31514736 | 0.69 | PDE10A (0.39) | HRH4PDE10ACNR2CNR1CSF1R | |
| SCHEMBL31514721 | 0.69 | PDE10A (0.37) | APPHRH4PDE10ACNR2CNR1 | |
| SCHEMBL2413779 | 0.68 | NPC1 (0.45) | APPHRH4CNR2CNR1IDO1 | |
| SCHEMBL29903760 | 0.65 | LMNA (0.43) | ALDH1A1LMNAPDE10A | |
| SCHEMBL26977954 | 0.65 | LMNA (0.43) | ALDH1A1LMNAPDE10A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190135793-A1 | HETEROCYCLIC INHIBITORS OF KDM5 FOR THE TREATMENT OF DISEASE | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2019-05-09 | — | — | US | disclosed |
| WO-2018213777-A1 | HETEROCYCLIC INHIBITORS OF KDM5 FOR THE TREATMENT OF DISEASE | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2018-11-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190135793-A1 | HETEROCYCLIC INHIBITORS OF KDM5 FOR THE TREATMENT OF DISEASE | KDM5A, KDM5B, KDM5C | APP 4504/4885ALDH1A1 1687/4885LMNA 1984/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.